News About: Pharm. Industry
Biopharmaceutical companies’ spread of acquisitions on medium & small companies
It seems biopharmaceutical companies will make moves on M&As on medium & small companies.
This is because biopharmaceutical companies which have focused on researches and developments are expanding themselves through...
Domestic companies have no choice but to silently wait until NOACs’ patent expiration
Although domestic pharmaceutical companies have tried to enter the market of novel oral anticoagulant(NOAC) generics, they have kept failed.
NOACs, which were confirmed to be used as a primary therapy with efficacy o...
Improvement measures on innovative drugs, biosimilars and insured drug prices
The two amendments on the pricing system for global innovative and biopharmaceutical drugs and the market drug price reduction system, which drew focused interests of the pharmaceutical industry from the beginning of ...
SK Chemicals approve commercialization of Xarelto generic for first timeThe first generic of novel oral anticoagulant(NOAC), which is rapidly invading the warfarin prescription market, was domestically approved.
Under the Patent-Linkage system, th...
|
Boksan Nice attracts KRW 52 billion investment from Japanese Suzuken
A domestic pharmaceutical distribution company succeeded in attracting a large-scale investment once again.
Boksan Nice Pharm(President Tae-eung Um) announced it has concluded a business and capital agreement with Su...
Japanese pharmaceutical companies record KRW 911.7 billion sales increased by 14.2%
Japanese multinational pharmaceutical companies branched in Korea continued upturns in the domestic market last year.
According to the analysis result of 8 Japanese companies’(6 companies and 12 companies balancing ...
Kyowa Hakko Kirin Korea appoint Suzuki as new CEO
On the 6th, the Japanese multinational pharmaceutical company, Kyowa Hakko Kirin Korea, announced appointment of Suzuki Shigeaki as a new CEO from the 1st of July.
Shigeaki Suzuki, the new CEO, is known as a profess...
Series of large pharmaceutical companies to establish venture capital firms
The top-ranked domestic pharmaceutical companies drew attention as establishing investment companies to support ventures for new drug development. Their purpose is to secure promising pipelines through the open innova...
AstraZeneca’s sharp conflicts between labor and management over reorganizationAstraZeneca Korea has suffered from conflicts against its labor union in the process of personnel reorganization.
AstraZeneca Korea conducted the ERP(Early Retirement Program) ...
|
Astellas become first Japanese pharmaceutical branch with KRW 200 billion annual sales
Astellas Pharma Korea(CEO Hae-do Jung) has enter the sales wall of KRW 200 billion for the first time as a Japanese multinational pharmaceutical company branched in the Korean market.
According to the electronic off...
